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Genetic Relationship between 
Schizophrenia and Nicotine 
Dependence
Jingchun Chen1,*, Silviu-Alin Bacanu2,3,*, Hui Yu4, Zhongming Zhao4, Peilin Jia4, 
Kenneth S. Kendler2,3, Henry R. Kranzler5, Joel Gelernter6, Lindsay Farrer7, Camelia Minica8, 
Rene Pool8, Yuri Milaneschi9, Dorret I. Boomsma8, Brenda W. J. H. Penninx8, 
Rachel F. Tyndale10, Jennifer J. Ware11, Jacqueline M. Vink12,13, Jaakko Kaprio14,15,16, 
Marcus Munafò11,17 , Xiangning Chen1,18, Cotinine meta-analysis group & FTND  
meta-analysis group 
It is well known that most schizophrenia patients smoke cigarettes. There are different hypotheses 
postulating the underlying mechanisms of this comorbidity. We used summary statistics from large 
meta-analyses of plasma cotinine concentration (COT), Fagerström test for nicotine dependence 
(FTND) and schizophrenia to examine the genetic relationship between these traits. We found that 
schizophrenia risk scores calculated at P-value thresholds of 5 × 10−3 and larger predicted FTND 
and cigarettes smoked per day (CPD), suggesting that genes most significantly associated with 
schizophrenia were not associated with FTND/CPD, consistent with the self-medication hypothesis. 
The COT risk scores predicted schizophrenia diagnosis at P-values of 5 × 10−3 and smaller, implying 
that genes most significantly associated with COT were associated with schizophrenia. These results 
implicated that schizophrenia and FTND/CPD/COT shared some genetic liability. Based on this shared 
liability, we identified multiple long non-coding RNAs and RNA binding protein genes (DA376252, 
BX089737, LOC101927273, LINC01029, LOC101928622, HY157071, DA902558, RBFOX1 and TINCR), 
protein modification genes (MANBA, UBE2D3, and RANGAP1) and energy production genes (XYLB, 
MTRF1 and ENOX1) that were associated with both conditions. Further analyses revealed that these 
shared genes were enriched in calcium signaling, long-term potentiation and neuroactive ligand-
receptor interaction pathways that played a critical role in cognitive functions and neuronal plasticity.
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Large scale genome wide association studies (GWASs) have identified risk genes for many complex human dis-
eases and traits (http://www.genome.gov/gwastudies/), including psychiatric disorders such as schizophrenia and 
nicotine dependence (ND)1–3. These GWASs also show that many human diseases and traits are polygenic in 
nature and the contribution of individual genes is limited4–6. Many of these studies have been deposited in the 
database of Genotypes and Phenotypes (dbGaP, http://www.ncbi.nlm.nih.gov/gap) and are available for second-
ary analyses. These datasets provide an opportunity to examine the genetic relationship between correlated traits, 
and to discover and identify risk genes shared across these traits.
Pleiotropy is a phenomenon in which a single locus affects multiple traits7,8. It accounts for at least a part of 
the genetic mechanism of many correlated human behaviors and diseases. Pleiotropy can take two forms: either 
a single process, leading to a cascade of downstream effects (sometimes described as “mediated pleiotropy”), or a 
single locus influencing multiple traits (sometimes described as “biological pleiotropy”)9. Schizophrenia is highly 
comorbid with cigarette smoking10. However, the underlying biology of this comorbidity is not well understood11. 
Several hypotheses have been proposed. The self-medication hypothesis postulates that schizophrenia patients 
smoke to reduce symptoms and antipsychotics-induced side effects and to improve their attention and working 
memory12. Alternatively, schizophrenia and ND could have shared some genetic liability (i.e., biological pleiot-
ropy)13, which is supported by recent studies of individual genes14–21. A third possibility is that smoking may be 
causal to schizophrenia (i.e., mediated pleiotropy)22. To explore the genetic relationship between schizophrenia 
and ND, we obtained the GWAS summary statistics from the Psychiatric Genomics Consortium (PGC) schizo-
phrenia analyses and ND related traits from our unpublished studies, and conducted polygenic analyses. Under 
the hypothesis of biological pleiotropy, we expect that genetic risk scores of schizophrenia and ND related traits 
predict each other; whereas self-medication would anticipate unidirectional (schizophrenia to ND traits) predic-
tion. In this article, we report the findings from these analyses.
Results
Nicotine dependence and schizophrenia share genetic liability. In these analyses, we calculated 
genetic risk scores for schizophrenia (supplementary Figure 1A) and tested whether the risk scores predicted 
FTND and CPD. The results were summarized in Table 1. Schizophrenia risk scores predicted FTND score and 
CPD at the thresholds of P ≤ 5 × 10−3, 5 × 10−2 and 5 × 10−1. The correlation coefficients at these thresholds were 
all positive, suggesting that a schizophrenia diagnosis was positively associated with cigarette smoking, consistent 
with the well-known comorbidity between schizophrenia and ND. However, schizophrenia risk scores explained 
only a very small fraction of the FTND and CPD traits.
FTND and COT risk scores (supplementary Figure 1B,C) were calculated for the subjects of the phase I PGC 
schizophrenia GWAS samples23 using the summary statistics from the FTND (n = 17,781) and COT (n = 4,548) 
GWAS meta-analyses. We then evaluated whether the genetic risk scores of COT and FTND could predict the 
schizophrenia diagnosis using logistic regression. The results were presented in Table 2. The COT risk scores 
calculated at the P-values of 5 × 10−5, 5 × 10−4 and 5 × 10−3 predicted schizophrenia diagnosis, but FTND risk 
scores failed to do so. For the P-values thresholds at which the COT risk scores predicted schizophrenia diagnosis, 
the beta coefficients were also positive, again, confirming the positive phenotypic correlation between ND and 
schizophrenia.
Identification of shared variants between ND and schizophrenia. Our reciprocal polygenic anal-
yses suggested that there were some shared genetic liability between schizophrenia and ND as defined by the 
FTND and COT traits. We then proceeded to identify the variants associated with both schizophrenia and ND 
traits. We computed joint P-values for each marker using the summary statistics from the schizophrenia and 
COT/FTND/TFC meta-analyses, and assigned a q-value to each of the joint P-values using an FDR method24,25. 
Table 3 listed the loci identified by the joint analyses with q-values ≤ 0.05. From the joint analyses between schiz-
ophrenia and COT, 11 loci reached genome-wide significance for association with both COT and schizophrenia, 
of which 2 loci had no known genes nearby and 6 were spliced ESTs or long non-coding RNAs. In the analyses 
between schizophrenia and FTND, 10 loci were identified, and 3 of them were ESTs or non-coding RNAs. The 
Threshold (P) Beta S.E. T_value Pr(>|T|) R2
FTND
 5 × 10−5 2.41E-04 0.000269 0.90 0.3708 0
 5 × 10−4 3.30E-04 0.000235 1.41 0.1599 1.00E-04
 5 × 10−3 3.91E-04 0.000194 2.01 0.0440 3.00E-04
 5 × 10−2 3.53E-04 0.000153 2.31 0.0211 4.00E-04
 5 × 10−1 3.22E-04 0.000118 2.73 0.0063 7.00E-04
CPD
 5 × 10−5 1.03E-04 8.77E-05 1.17 0.2424 0
 5 × 10−4 1.37E-04 7.64E-05 1.79 0.0736 1.00E-04
 5 × 10−3 1.71E-04 6.32E-05 2.71 0.0067 5.00E-04
 5 × 10−2 1.56E-04 4.99E-05 3.13 0.0018 6.00E-04
 5 × 10−1 1.29E-04 3.84E-05 3.37 0.0008 8.00E-04
Table 1.  Schizophrenia risk score prediction of FTND and CPD.
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joint analyses between schizophrenia and TFC yielded 15 significant loci. The CHRNA5-CHRNA3-CHRNB4 
locus was the only one identified by all three smoking traits. In addition to some genes known to be associated 
with schizophrenia (HLA-B and MAD1L1), we also identified novel non-coding RNAs and RNA binding protein 
genes (DA376252, BX089737, LOC101927273, LINC01029, LOC101928622, HY157071, DA902558, RBFOX1 
and TINCR), post-translation modification genes (MANBA, UBE2D3 and RANGAP1) and energy production 
genes (XYLB, MTRF1 and ENOX1).
Pathway enrichment and network interaction analyses. We further explored the pathways shared by 
schizophrenia and ND by selecting all markers with q-values less than 0.16 from the joint analyses between schiz-
ophrenia and smoking traits. After mapping the markers to genes, the genes showing potential association with 
schizophrenia and COT/FTND/TFC were pooled to search for pathways enriched in both conditions. In these 
analyses, we selected only the genes identified by at least 2 of the 3 smoking traits, yielding a total of 146 genes. 
After filtering out the human leukocyte antigen genes (HLA-B, HLA-C, HLA-DOA, HLA-DQA1, HLA-DQB1, 
HLA-DRB1, and HLA-G) due to their strong linkage disequilibrium26, we used the remaining 139 genes in path-
way analyses.
Our analyses identified 16 unique pathways that were shared between schizophrenia and ND (Table 4). The 
most noticeable pathways were Calcium Signaling, Long-Term Potentiation, Neuroactive Ligand-Receptor 
Interaction, Phosphatidylinositol Signaling, Cell Adhesion Molecules, and Regulation of Actin Cytoskeleton 
pathways. Some of these pathways (Calcium Signaling, Long-Term Potentiation, Cell Adhesion Molecules, and 
Regulation of Actin Cytoskeleton) had been reported to be involved in schizophrenia27–32, others (Cell Adhesion 
Molecules and Neuroactive Ligand-Receptor Interaction) had been implicated in ND33,34. We found that these 
pathways were enriched in the genes associated with both ND and schizophrenia. Additionally, pathways involved 
in cardiomyopathy, GnRH signaling, gastric acid secretion and Alzheimer’s disease were also found to be shared 
between schizophrenia and ND. In the pathway network interaction analyses, we found a network of crosstalk 
between pathways (Fig. 1), with the Long-Term Potentiation located at the center of these interactions.
Discussion
It is well known in psychiatric clinics that a large proportion of schizophrenia patients smoke cigarettes and 
smoke heavily13. The dominant hypothesis to explain the comorbidity is self-medication12, i.e., that schizophre-
nia patients smoke to ameliorate impairments in cognitive function and suppress psychotic symptoms. Another 
hypothesis contends that schizophrenia and ND share some genetic liability, and the high prevalence rate of 
cigarette smoking in schizophrenia patients is a manifestation that is partially due to the common liability13. A 
third possibility is that smoking may be a risk factor for the development of schizophrenia, given that smoking 
initiation typically predates the onset of schizophrenia22. These three hypotheses are not mutually exclusive, and 
all three may contribute to the observed co-occurrence of schizophrenia and smoking.
Previous studies examining this issue have largely focused on individual functions/symptoms or genes using 
relatively small sample sizes. Here we took a systematic approach, and examined the entire genome using large 
GWAS datasets and multiple traits. We observed different patterns between the reciprocal polygenic analyses 
(comparing Tables 1 and 2). When we used the genetic risk scores of schizophrenia to predict ND traits, the 
association was evident at P-values ≥ 5 × 10−3, with the association strength increased as the P-value threshold 
became larger (Table 1). Given that the PGC schizophrenia GWAS did not control for smoking status and quan-
tity, and there was a large difference of smoking prevalence between schizophrenia patients and controls (on 
average, 65% or more schizophrenia patients smoke, and about 20% people smoke in the general population), we 
would expect that the PGC schizophrenia GWAS identify top candidates for ND related traits. But what we found 
was not the case. These top ranked candidates (i.e. those with P-values ≤ 5 × 10−5) from the PGC schizophrenia 
meta-analysis1 were not predict ND related traits. A likely explanation for these results is that genes most strongly 
associated with schizophrenia do not directly contribute to the smoking behaviors in schizophrenia patients. In 
other words, the reason why schizophrenia patients smoke is that they want to improve their cognitive functions 
Threshold (P) Beta S.E. Wald Z Pr(>|Z|) R2
Cotinine
 5 × 10−5 0.0459 0.0169 2.72 0.0066 0.0006
 5 × 10−4 0.0583 0.0169 3.45 0.0006 0.0010
 5 × 10−3 0.0435 0.0169 2.58 0.0100 0.0005
 5 × 10−2 0.0035 0.0170 0.20 0.8384 3.4E-06
 5 × 10−1 − 0.0226 0.0172 − 1.32 0.1886 0.0001
FTND
 5 × 10−5 0.0220 0.0242 0.91 0.3641 0.0001
 5 × 10−4 0.0227 0.0507 0.45 0.6537 2.5E-05
 5 × 10−3 0.0331 0.0617 0.54 0.5913 3.5E-05
 5 × 10−2 0.0033 0.0323 0.10 0.9174 1.3E-06
 5 × 10−1 0.0281 0.0292 0.96 0.3362 0.0001
Table 2.  Genetic risk score to nicotine dependence prediction of schizophrenia diagnosis*. *R2 is the 
Nagelkerke’s R2 obtained by the R package fmsb.
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and to suppress psychotic symptoms, not because that they are addicted to nicotine as regular smokers in the 
general population do. These results are consistent with the self-medication hypothesis.
In contrast, when we used COT risk scores to predict schizophrenia diagnosis, we found that smaller P-values 
produced stronger signals (Table 2), indicating that genes most strongly associated with ND were associated with 
schizophrenia. The results imply that either ND and schizophrenia share some genetic liability, or ND is a risk 
factor of schizophrenia. These fit the predictions of the shared liability hypothesis and that smoking is a causal risk 
for schizophrenia. Of note, these two explanations are not mutually exclusive. But without data on smoking of the 
patients we are unable to test the latter possibility (e.g., by stratifying our sample on smoking status).
Assuming biological pleiotropy to be the underlying mechanism, we devised a test to discover the variants 
shared between ND and schizophrenia. Using this approach, we identified multiple genes associated with both 
conditions (Table 3). Of these genes, the CHRNA5-CHRNA3-CHRNB4 cluster had been found to be associated 
with CPD2,3 and other ND related traits, and it was reported to be associated with schizophrenia in the latest 
schizophrenia GWAS meta-analysis from PGC1. Several of the genes had been reported to be associated with 
schizophrenia (HLA-B and MAD1L1)28 and epilepsy (KCNT1, PRICKLE2 and RBFOX1)35–37, suggesting that they 
might play a role in smoking behaviors as well. Our analyses also identified some novel genes shared between 
schizophrenia and ND, including a group of long non-coding RNAs and RNA binding protein genes (DA376252, 
BX089737, LOC101927273, LINC01029, LOC101928622, HY157071, DA902558, RBFOX1 and TINCR), a group 
of post-translation modification genes (MANBA, UBE2D3, and RANGAP1) and a group of energy production 
SNP Chr Location (bp) Z (ND) Z (SCZ) P-value Q-value Gene symbol # markers
COT
 rs798015 1 117,320,907 − 3.71 − 3.69 5.08E-08 0.0020 DA376252 3
 rs9850756 3 18,905,739 − 3.71 3.62 8.72E-08 0.0030 DA733783 1
 rs709071 3 191,426,311 − 3.46 3.51 2.85E-07 0.0081 – 1
 rs12640124 4 118,775,172 3.61 − 3.50 2.12E-07 0.0063 BX089737 3
 rs2442720 6 31,320,277 − 3.49 4.62 2.26E-07 0.0067 HLA-B 1
 rs11779524 8 8,618,613 3.85 3.81 1.89E-08 0.0008 CF594265 4
 rs56235824 9 11,039,320 3.44 3.55 3.38E-07 0.0090 – 1
 rs11788261 9 138,611,139 3.80 3.51 1.95E-07 0.0060 KCNT1 2
 rs8042374 15 78,908,032 7.69 7.04 3.48E-24 1.68E-17 CHRNA5/CHRNA3/CHRNB4 270
 rs6650723 18 53,524,269 3.76 3.51 2.07E-07 0.0062 DA696352/LOC101927273 5
 rs7228837 18 75,817,606 4.23 3.65 6.64E-08 0.0024 LINC01029 19
FTND
 rs56335113 1 30,427,639 3.80 5.85 2.02E-08 0.0021 – 10
 rs36025078 2 155,883,716 − 3.90 − 3.59 1.13E-07 0.0061 – 1
 rs188499496 3 38,450,183 − 3.93 − 3.62 8.82E-08 0.0050 XYLB 2
 rs11917643 3 64,171,754 3.62 − 4.17 8.41E-08 0.0048 PRICKLE2 6
 rs76923559 4 34,053,926 − 3.93 − 3.79 2.35E-08 0.0023 LOC101928622 3
 rs147093127 5 152,086,293 3.67 4.01 5.70E-08 0.0037 LINC01470 1
 rs9322751 6 104,015,759 − 3.51 − 3.54 2.03E-07 0.0089 HY157071 6
 rs4994764 7 1,928,662 − 3.90 − 4.32 9.17E-09 0.0012 MAD1L1 18
 rs3910267 11 130,810,282 − 3.84 5.71 1.50E-08 0.0018 SNX19 21
 rs147144681 15 78,900,908 − 7.62 − 5.55 7.85E-16 5.66E-09 CHRNA5/CHRNA3/CHRNB4 106
TFC
 rs4658015 1 196,053,435 3.51 3.36 5.91E-07 0.0094 – 1
 rs1069267 3 38,435,023 − 3.63 − 4.43 8.02E-08 0.0015 XYLB 3
 rs11722779 4 103,827,488 4.22 − 4.30 6.00E-10 0.0001 MANBA/UBE2D3/SLC9B2 315
 rs2717737 8 18,459,343 − 3.36 3.73 6.05E-07 0.0096 PSD3 1
 rs13264022 8 21,293,046 3.50 4.01 2.16E-07 0.0038 DA902558 15
 rs7959287 12 103,601,638 3.84 4.49 1.54E-08 0.0003 – 5
 rs9594516 13 41,849,360 3.64 3.77 7.33E-08 0.0014 MTRF1 1
 rs112531467 13 43,865,047 − 3.66 3.52 1.86E-07 0.0033 ENOX1 1
 rs181676509 14 104,242,531 − 3.67 − 3.98 5.73E-08 0.0011 C14ORF2 15
 rs147144681 15 78,900,908 − 5.50 − 5.55 1.49E-15 1.08E-08 CHRNA5/CHRNA3/CHRNB4 72
 rs17665477 16 6,700,889 − 3.69 3.80 5.16E-08 0.0010 RBFOX1 11
 rs12462853 19 5,538,936 3.45 − 3.39 4.82E-07 0.0078 TINCR 2
 rs62202174 20 20,461,125 − 3.38 − 4.24 5.26E-07 0.0085 RALGAPA2 1
 rs5758274 22 41,664,539 3.64 − 4.45 7.43E-08 0.0014 RANGAP1 1
 rs8135804 22 42,334,660 3.40 3.57 4.54E-07 0.0074 CENPM 12
Table 3. Joint testing of association with schizophrenia and smoking traits.
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genes (XYLB, MTRF1 and ENOX1). Long non-coding RNAs were suggested to play a role in schizophrenia38,39, 
the identification of multiple long non-coding RNAs was intriguing.
Phenotype comorbidity is common in complex diseases and traits7,8. Pleiotropy, or shared genetic liability, 
may be an underlying mechanism of these comorbidities. Under this condition, different approaches have been 
developed to identify genes shared by the comorbid conditions40,41, and these approaches seem more powerful 
than standard GWAS8,42. Another advantage of these methods is that they can use the large number of GWAS 
datasets produced by a single phenotype/trait analyses. The approach we used to identify these shared loci is 
conservative. In our analyses, we excluded all markers reaching genome-wide significance from both schizophre-
nia and smoking traits and required a balanced contribution from both traits. Under this condition, if a marker 
reached genome wide significance for schizophrenia but had a modest association with ND traits (say P-values 
between 10−4 to 5 × 10−6), it was excluded from our joint testing. Similarly, some markers would be excluded if 
they reached genome wide significance in ND traits. Because the GWASs used have different sample sizes, and 
Pathway Genes found in pathway
# gene in 
pathway
# gene 
observed
# gene 
expected
Observed/
expected ratio
Raw 
P-value
Adjusted 
P-value
Calcium signaling pathway
ATP2B2, CACNA1C, 
CACNA1I, CHRM3, 
ITPR1, ITPR2
177 6 0.57 10.59 2.41E-05 0.0004
Long-term potentiation CACNA1C, ITPR1, ITPR2, PPP1CB 70 4 0.22 17.86 7.81E-05 0.0007
Neuroactive ligand-receptor interaction
CHRM3, CHRNA3, 
CHRNA5, CHRNB4, 
NR3C1, THRB
272 6 0.87 6.89 0.0003 0.0011
Salivary secretion ATP2B2, CHRM3, ITPR1, ITPR2 89 4 0.28 14.05 0.0002 0.0011
Pancreatic secretion ATP2B2, CHRM3, ITPR1, ITPR2 101 4 0.32 12.38 0.0003 0.0011
Vascular smooth muscle contraction CACNA1C, ITPR1, ITPR2, PPP1CB 116 4 0.37 10.78 0.0005 0.0013
Oocyte meiosis ITPR1, ITPR2, PPP1CB, SPDYA 112 4 0.36 11.16 0.0005 0.0013
Phosphatidylinositol signaling system INPP5K, ITPR1, ITPR2 78 3 0.25 12.02 0.0020 0.0036
Gastric acid secretion CHRM3, ITPR1, ITPR2 74 3 0.24 12.67 0.0018 0.0036
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) CACNA1C, ITGAV, SGCD 74 3 0.24 12.67 0.0018 0.0036
Hypertrophic cardiomyopathy (HCM) CACNA1C, ITGAV, SGCD 83 3 0.27 11.30 0.0024 0.0039
Dilated cardiomyopathy CACNA1C, ITGAV, SGCD 90 3 0.29 10.42 0.0031 0.0046
GnRH signaling pathway CACNA1C, ITPR1, ITPR2 101 3 0.32 9.28 0.0042 0.0058
Cell adhesion molecules (CAMs) ITGAV, NCAM2, PTPRM 133 3 0.43 7.05 0.0091 0.0117
Alzheimer’s disease CACNA1C, ITPR1, ITPR2 167 3 0.53 5.61 0.0167 0.0188
Regulation of actin cytoskeleton CHRM3, ITGAV, PPP1CB 213 3 0.68 4.40 0.0313 0.0331
Table 4.  Pathways enriched in schizophrenia and smoking traits.
Figure 1. Pathway crosstalk network. The size of the node is proportional to the P-values of pathway 
enrichment test. The thickness of the edge is proportional to the P-values of pathway crosstalk.
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therefore varied in their statistical power, it is inevitable that we would miss some markers from the more power-
ful GWAS when we required balanced summary statistics in the joint testing.
Our pathway analyses identified multiple pathways shared by schizophrenia and ND. The most significant 
pathways were Calcium Signaling, Long-Term Potentiation and Neuroactive Ligand-Receptor Interaction. These 
pathways are involved in neurotransmitter transduction and communication between neurons, and they are 
essential for cognitive functions. These pathways have been shown to be involved in schizophrenia28,43,44 and 
ND45,46. The Cell Adhesion Molecules and Regulation of Actin Cytoskeleton pathways have also been reported 
in schizophrenia31,47–49 and ND45,50,51. Thus, our results are consistent with these studies. It is worth noting that 
the cardiomyopathy pathways were identified in our analyses and that, in a previous study, we found that CMYA5 
was associated with schizophrenia52. Another gene, NDUFV2, causative to hypertrophic cardiomyopathy53,54, 
the genetic form of cardiomyopathy, was also found to be associated with schizophrenia55–57. Pathway crosstalk 
analyses showed that many of these pathways interact with each other and together they form an interlinked 
network with the Long-Term Potentiation pathway at the center of these interactions. In animal studies, nico-
tine alters long-term potentiation58–60 and learning and memory61. In humans, smoking may alleviate cognitive 
impairment62, and both nicotine withdrawal and schizophrenia are associated with cognitive impairments63,64. 
Thus, compensating cognitive impairments may be a common motivational factor between regular smokers and 
schizophrenia patients.
In summary, our results supported the self-medication hypothesis. We also found evidence that schizophrenia 
and ND share some genetic liability and these results did not contradict the hypothesis that smoking was a causal 
risk factor for schizophrenia. Assuming shared liability and a balanced contribution, we identified novel candi-
date genes associated with both schizophrenia and ND. Analyses of the shared genes revealed multiple pathways 
and an interacting network centered on long-term potentiation. These results provided some new insights for our 
understanding of smoking behaviors in both schizophrenia patients and the general population.
Methods
Phenotypes and GWAS datasets. For schizophrenia, we obtained the summary statistics from the 
PGC GWAS of schizophrenia1. This study used 52 independent samples, of them 46 were case control samples 
of European ancestry, 3 were Asian case control samples and 3 were European family samples. Since the sam-
ples were collected from different countries, both the criteria for Diagnostic and Statistical Manual of Mental 
Disorders (DSM) and International Classification of Diseases (ICD) were used in the diagnosis of the patients. 
Please see original paper1 for details. We selected to use the summary statistics of the 46 European case control 
samples (32,405 cases and 46,839 controls). For ND-related traits, we used the summary statistics of our cotinine 
study65 and 2 unpublished datasets (manuscripts in preparation). One data used the sum scores of the Fagerström 
Test for Nicotine Dependence (FTND)66 as a trait, which is a commonly used phenotype for ND based on self-re-
ported smoking behaviors. The second data used a single item of the FTND questionnaire, “How soon after you 
wake up do you smoke your first cigarette”, or time to smoke the first cigarette (TFC) as a trait. This question can 
be seen as a measure of nicotine withdrawal since the half-life of nicotine in the human body is about 2 hours67. 
Smokers often experience nicotine withdrawal in the morning after not smoking overnight. The third data65 used 
the plasma cotinine concentration (COT) as a trait. Cotinine is the major metabolite of nicotine, and its half-life 
is much longer than that of nicotine. Therefore, its concentration in plasma can be considered an index of nicotine 
intake in recent days68,69. Because the quantity of nicotine intake is one of the most important measures of ND, 
COT may be considered a measure of ND as well. In these studies, FTND, TFC and COT were treated as quan-
titative traits. The sample size for FTND was 16,237, excluding the Netherlands Twin Registry sample because 
some of its subjects were also used in COT GWAS. The sample sizes for TFC and COT were 15,705 and 4,575 
respectively. The FTND and TFC measures were derived from the same subjects, therefore, only FTND was used 
in polygenic analyses. TFC were used only for the identification of shared genes between schizophrenia and ND 
related phenotypes. The samples used in these 3 ND related GWASs were listed in Supplementary Table S1. All 
subjects used in this study were of European ancestry.
Polygenic analyses. Schizophrenia risk scores were calculated for 9 independent smoking related studies 
(Table S1, n = 10,794) with FTND and CPD measures using the summary statistics from the PGC schizophrenia 
meta-analysis. The control subjects from the Molecular Genetics of Schizophrenia (MGS) were included in the 
GWASs of both FTND and PGC schizophrenia, therefore they were excluded from this analysis. Risk scores for 
COT and FTND were calculated for 13,326 individuals from the NIMH genetics consortium repository (https://
www.nimhgenetics.org/). We estimated the risk scores for each trait using the algorithms implemented in the 
PLINK software70. Specifically, the risk score for an individual was the sum of the number of risk alleles mul-
tiplied by the logarithm of odds ratio (OR, for schizophrenia) or beta coefficient (for FTND and COT), which 
was then normalized subsequently by the product of maximal number of risk alleles and log(OR)s/beta coeffi-
cients. For each trait, we calculated risk scores at 5 P-value thresholds: 5 × 10−5, 5 × 10−4, 5 × 10−3, 5 × 10−2 and 
5 × 10−1. The numbers of markers used to calculate schizophrenia risk scores at these thresholds were 6,014, 
94,804, 268,070, 1,021,476 and 5,370,899. The numbers of markers used for FTND and COT were 731, 6,312, 
55,378, 500,542 and 4,752,196; and 1,621, 6,357, 48,575, 473,100, and 4,737,313 respectively. We then tested 
whether schizophrenia risk scores predicted FTND scores and vice versa using logistic (schizophrenia) and linear 
regression (FTND scores). Since the number of cigarettes smoked per day (CPD) was available from the FTND 
datasets, we also tested whether the genetic risk scores for schizophrenia predicted the CPD phenotype. Because 
we did not have individual genotypes for all datasets used in the COT meta-analyses, we used only the COT risk 
score to predict schizophrenia diagnosis. Sex, age and study were included as covariates in regression analyses.
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Identification of shared risk genes. While there are papers looking at pleiotropy from a conditional FDR 
point of view71, we arrive to qualitatively similar conclusions using a somewhat simpler approach of family-wise 
error rate. Our test attempts to discover shared risk genes between schizophrenia and ND using summary statis-
tics from their respective GWASs. To ensure that such a test is not overly influenced by a strong signal in just one 
trait, we implemented a “weakest link” approach (i.e., choosing the larger P-value of the pair of trait tests at the 
SNP under investigation)72. In more detail, let Xj and Pj be the χ 2 distributed statistics and their associated (back-
ground enrichment adjusted) P-values, j = 1, … , m, for association tests between the m traits and a SNP. As the 
overlap statistic of all traits we use =R Pmax
j
j (or, alternatively, = | |T Xmin
j
j ). Under the assumption that the 
trait tests are independent, the P-value (also denoted as overlap P-value) for a given overlap statistic, r, at a SNP is 
≤ = ∏ ≤=P R r P P r( ) ( )jm j1 . If we further assume that (under the null hypothesis - H0) none of the traits is asso-
ciated with the genetic variant, the overlap P-value simplifies to P(R ≤ r) = rm (1). Otherwise, P(Pj ≤ r) can be 
computed based on the distribution of the j-th trait P-values. For instance, for two phenotype configuration and 
a putative threshold of 5 × 10−8, the parametric version of our method requires that, for a significant pleiotropic 
signal, the p-values for both phenotypes to be < 2.2 × 10−4 (= −x5 10 8 ). This substantially less than 5 × 10−8 
p-value threshold is similar in spirit to the one from Andeassen et al.71 While the overlap p-value (1) does elimi-
nate most of the influence of an extreme signal for one phenotype, it does not eliminate it completely. However, 
for a putative threshold of 5 × 10−8 in (1), under the worst case scenario of an extreme signal in one phenotype, 
the false positive rate per SNP is still rather small, i.e. 2.2 × 10−4. Even more, as seen in Andreassen et al., the false 
positive rate is likely to be substantially lower. Moreover, a worst-case-scenario 2.2 × 10−4 false positive rate is 
adequate for the pathway analyses73. We used FDR24 to evaluate the approximate significance of the genetic over-
lap (described by relation (1)) between schizophrenia and smoking phenotypes. To select promising markers for 
pathway and network analyses we applied a threshold of q-value ≤ 0.16, corresponding to a factor of 2 in Akaike 
Information Criterion penalty in a likelihood ratio χ 2 test with 1 degree of freedom.
Pathway and network analyses. We conducted pathway enrichment analysis of genes with at least one 
marker with q-values lower than 0.16 from the joint testing of schizophrenia and COT/FTND/TFC traits. If a 
marker was within a gene region, it was assigned to the gene; otherwise, it was mapped to its most proximate 
gene using the 50-kb flanking regions (both 5′ and 3′ sides). Genes identified using SNPs associated with COT, 
FTND, or TFC were merged for the pathway enrichment analysis, for which we used the hypergeometric test 
implemented in the tool WebGestalt (2013 update)74 and the canonical pathways from the Kyoto Encyclopedia 
of Genes and Genomes (KEGG) database. We required each pathway to have at least three genes from our gene 
list and no more than 300 genes from the reference genome. The P-values from hypergeometric tests were further 
adjusted by the Benjamini-Hochberg method23. Only pathways with adjusted P-values < 0.05 were considered 
statistically significantly enriched.
We further examined pathways interaction using the Characteristic Sub-Pathway Network (CSPN) algo-
rithm31,75 the human protein-protein interaction (PPI) network76. We restricted the analysis specifically to the 
aforementioned merged gene set and their enriched pathways. In the final step, we selected the significant path-
way interaction pairs based on permutation P-values less than 0.05.
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